Canada markets closed

Sage Therapeutics, Inc. (SAGE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
58.80-14.06 (-19.30%)
At close: 4:00PM EDT
58.80 0.00 (0.00%)
After hours: 04:12PM EDT
Sign in to post a message.
  • J
    Jerry
    Thanks Chevy. Also, last six months only approx. 5 thousand shares traded by insiders and it was a purchase. In a buyout purchase price would be over 100 per considering cash position and outstanding shares.
  • J
    Jerry
    Even if share price stays here I wouldn't be too concerned. For those saying bk. PLease!!!! A company with practically zero debt compared to cash position a plenty. This is not one of Trumps casinos.
  • t
    thomas
    couple more analyst comments
    Jefferies the data would enable sage shares to move higher long term and that the study raises the odds that fda will approve drug
    MIZUHO the difference between treatment group and placebo after 15 days was too small to be considered meaningful. In addition the safety profile does not appear very attractive with such limited efficacy leaving us to wonder what role the drug might have in clinical practice.
  • J
    JANICE
    Sage says "positive" results. I am going to check my dictionary and see if the definition of "positive" has changed? Still long and not liking it.
  • J
    Justin
    This is manipulation pure and simple. It should be against the law. There is collusion going on. I looked at the value of the options for this stock over the weekend and the premiums many standard deviations past the norm even down at the $50 level. And this is when the stock was trading at $78. So SOMEONE knew that this stock was going to take a big tumble even on relatively good news. People got together and decided they were going to short this no matter what. Again, should be illegal!
  • m
    mohda
    Please buy now all you have, Current price 59 sell today 72.
    News are great and drug showed positive result, BTW, early morning stock traded at 82
  • t
    thomas
    first analyst comment I can find
    The Phase 3 WATERFALL study for zuranolone in major depressive disorder met its primary and most of the secondary endpoints of efficacy, along with an in line safety profile, Piper Sandler analyst Yasmeen Rahimi tells investors in a research note. The selloff in Sage Therapeutics shares this morning is an overreaction to the efficacy not being statistically significant at 42 days, says the analyst. Rahimi highlights that 86.1% of patients still had a HAM-D response after treatment ended and notes the study was not powered to show a statistical significance at 42 days. Despite the Street's speculations, the current risk benefit profile for zuranolone is favorable with a potential for approval and strong adoption in a population with high unmet need, contends Rahimi. She keeps an Overweight rating on Sage Therapeutics with a $100 price targe
  • J
    Jerry
    Please remember that when stock price cut in half in 2019 sales were just over 6 million and sales are now over 1 billion. Plus company believes phase 3 was a success. Some non medical people are debating it.
  • J
    Jerry
    The conference call is the opposite of what RBC analyst is saying. I am calling them again to address negative article.
  • T
    TL Holland
    They are already recruiting for next phase of depression study. Positive results published.
  • A
    Anonymous
    Wow!! SAGE achieved the clinical study results
    This stock will rise up soooon
  • N
    Nermeen
    SAGE-BIOGEN positive results, a good stock to buy asap!!!!! It will reach 100$ soon!!!!!!!
  • B
    Bechody
    Based on the results, patients treated with zuranolone showed no improvement from depressive symptoms at Day 15. The stock is down 20% in pre-mkt. Selllllllll now.
  • b
    bocash
    I couldn’t be happier with the daily emails I get from (http://Fairstox.com). They give me the best daily advice based on stock market news and help me make wiser decisions when it comes to investing. An absolute must for any investor!
  • a
    abd
    Will fly now
  • J
    Jerry
    Listening to conference call. Many more positives than negatives. All drugs in MD's handbook have side effects.
  • B
    Ben
    Does anyone know why? I was just here from TA saw it break triangle but why’d it tank today
  • A
    Anonymous
    anyone understand why it's going down and results are good???
  • M
    MD
    AXSM is the next best CNS company, AXS-05 PDUFA in August.
  • J
    Jerry
    Positive results for a depression drug when mental illness is rising. Shorting this stock short term for a day may work, longer you are playing with lit matches.